Home » Regeneron Begins Clinical Trials of COVID-19 Antibody Cocktail
Regeneron Begins Clinical Trials of COVID-19 Antibody Cocktail
Regeneron has begun the first clinical trial of its investigational COVID-19 antibody cocktail REGN-COV2 for the prevention and treatment of COVID-19.
The set of trials it plans to undertake consists of four separate populations: hospitalized patients, nonhospitalized patients, uninfected individuals in groups at high-risk of exposure and uninfected individuals with close exposure to a COVID-19 patient.
Regeneron said it is scaling production to have hundreds of thousands of preventative doses or tens of thousands of larger treatment doses per month by the end of August.
Upcoming Events
-
07May
-
14May
-
30May